First-in-class biopharmaceutical for treating osteoarthritis

Levicept is developing LEVI-04 (p75NTR-Fc), a novel biological agent for the treatment of chronic pain associated with Osteoathritis. LEVI-04 delivers neurotrophin homeostasis to provide analgesia while maintaining the neurotrophin function required for cartilage and bone repair.

CEO  Simon Westbrook

Advent Contact  Raj Parekh

Advent invested in the Series A in 2014.
Private Companies